ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ALX also affected CML stem/progenitor cells that represent a clinical issue as they are resistant to Tyrosine Kinase Inhibitors (TKIs) that target the BCR::ABL1 oncogenic driver of CML.